<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hemochromatosis" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hemochromatosis</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">HFE</italic>-Associated Hereditary Hemochromatosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Seckington</surname>
            <given-names>Rebecca</given-names>
          </name>
          <email>rebecca.seckington@uqconnect.edu.au</email>
          <aff>University of Queensland School of Medicine<break/>Brisbane, Queensland, Australia</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Powell</surname>
            <given-names>Lawrie</given-names>
          </name>
          <degrees>AC, MD, PhD</degrees>
          <email>lawrie.powell@qimrberghofer.edu.au</email>
          <aff>Royal Brisbane &#x00026; Women&#x02019;s Hospital and University of Queensland<break/>Brisbane, Queensland, Australia</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2000-04-03" date-type="created">
          <day>3</day>
          <month>4</month>
          <year>2000</year>
        </date>
        <date iso-8601-date="2015-09-17" date-type="updated">
          <day>17</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="gcps" document-type="chapter">Greig Cephalopolysyndactyly Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hfg" document-type="chapter">Hand-Foot-Genital Syndrome</related-object>
      <abstract id="hemochromatosis.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis <italic toggle="yes">(HFE</italic>-HH) is characterized by inappropriately high absorption of iron by the gastrointestinal mucosa. The phenotypic spectrum of <italic toggle="yes">HFE</italic>-HH is now recognized to include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Those with clinical <italic toggle="yes">HFE</italic>-HH, in which manifestations of end-organ damage secondary to iron storage are present;</p>
            </list-item>
            <list-item>
              <p>Those with biochemical <italic toggle="yes">HFE</italic>-HH, in which the only evidence of iron overload is increased transferrin-iron saturation and increased serum ferritin concentration;</p>
            </list-item>
            <list-item>
              <p>Non-expressing p.Cys282Tyr homozygotes, in whom neither clinical manifestations of <italic toggle="yes">HFE</italic>-HH nor iron overload is present.</p>
            </list-item>
          </list>
          <p>Clinical <italic toggle="yes">HFE</italic>-HH is characterized by excessive storage of iron in the liver, skin, pancreas, heart, joints, and testes. In untreated individuals, early symptoms may include: abdominal pain, weakness, lethargy, and weight loss; the risk of cirrhosis is significantly increased when the serum ferritin is higher than 1,000 ng/mL; other findings may include progressive increase in skin pigmentation, diabetes mellitus, congestive heart failure, and/or arrhythmias, arthritis, and hypogonadism. Clinical <italic toggle="yes">HFE</italic>-HH is more common in men than women.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of clinical <italic toggle="yes">HFE</italic>-HH in individuals with clinical findings consistent with <italic toggle="yes">HFE</italic>-HH and the diagnosis of biochemical <italic toggle="yes">HFE</italic>-HH are typically based on finding elevated transferrin-iron saturation 45% or higher and serum ferritin concentration above the upper limit of normal (i.e., &#x0003e;300 ng/mL in men and &#x0003e;200 ng/mL in women) and two pathogenic variants on confirmatory <italic toggle="yes">HFE</italic> molecular genetic testing. Although serum ferritin concentration may increase progressively over time in untreated individuals with <italic toggle="yes">HFE</italic>-HH, it is not specific for <italic toggle="yes">HFE</italic>-HH, and therefore cannot be used alone for identification of individuals with <italic toggle="yes">HFE</italic>-HH.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Clinical <italic toggle="yes">HFE</italic>-HH: treatment by phlebotomy (removal of blood) to maintain serum ferritin concentration at &#x02264;50 ng/mL. Biochemical <italic toggle="yes">HFE</italic>-HH: start phlebotomy when serum ferritin concentration is &#x0003e;500 ng/mL. Non-expressing p.Cys282Tyr homozygotes: phlebotomy is not required, as these individuals do not have iron overload.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Vaccination against hepatitis A and B.</p>
          <p>
            <italic toggle="yes">Surveillance:</italic>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical <italic toggle="yes">HFE</italic>-HH: Once the serum ferritin concentration is &#x0003c;50 ng/mL, routine monitoring of serum ferritin concentration every three to four months; routine screening for hepatocellular cancer (HCC) in individuals who have cirrhosis.</p>
            </list-item>
            <list-item>
              <p>Biochemical <italic toggle="yes">HFE</italic>-HH and non-expressing p.Cys282Tyr homozygotes: Begin annual measurement of serum ferritin concentration when ferritin concentration exceeds normal levels.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Medicinal iron, mineral supplements, excess vitamin C, and uncooked seafood; alcohol consumption in those with hepatic involvement.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Offer molecular genetic testing to the adult sibs of a proband homozygous for p.Cys282Tyr to allow early diagnosis and surveillance.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">HFE</italic>-HH is inherited in an autosomal recessive manner.</p>
          <p><italic toggle="yes">Risk to sibs:</italic> When both parents of an affected individual are heterozygous for the <italic toggle="yes">HFE</italic> pathogenic variant, the risk to sibs of inheriting two <italic toggle="yes">HFE</italic> pathogenic variants is 25%. However, because the carrier frequency for an <italic toggle="yes">HFE</italic> pathogenic variant in persons of European origin is high (11%, or 1/9), on occasion one parent of an affected individual has two abnormal <italic toggle="yes">HFE</italic> alleles. In such instances, the risk to each sib of inheriting two <italic toggle="yes">HFE</italic> pathogenic variants is 50%.</p>
          <p><italic toggle="yes">Risk to offspring:</italic> Offspring of an individual with <italic toggle="yes">HFE</italic>-HH inherit one <italic toggle="yes">HFE</italic> pathogenic variant from the affected parent. Because of the 1/9 chance that the other parent is a carrier for a mutant <italic toggle="yes">HFE</italic> allele, the risk to the offspring of inheriting two <italic toggle="yes">HFE</italic> pathogenic variants is approximately 5%.</p>
          <p><italic toggle="yes">Prenatal testing:</italic> Although prenatal testing would be technically feasible for pregnancies at 25% or more risk, such requests would be highly unusual because <italic toggle="yes">HFE</italic>-HH is an adult-onset, treatable disorder with low clinical penetrance.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hemochromatosis.Diagnosis">
        <title>Diagnosis</title>
        <p>The American Association for the Study of Liver Disease (AASLD) has published practice guidelines for diagnosis and management of hemochromatosis [<xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">full text</ext-link>).</p>
        <sec id="hemochromatosis.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Diagnosis of <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis <italic toggle="yes">(HFE</italic>-HH) should be suspected in individuals with</p>
          <p><bold>Clinical signs</bold> of advanced iron overload, including:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hepatomegaly</p>
            </list-item>
            <list-item>
              <p>Hepatic cirrhosis</p>
            </list-item>
            <list-item>
              <p>Hepatocellular carcinoma</p>
            </list-item>
            <list-item>
              <p>Diabetes mellitus</p>
            </list-item>
            <list-item>
              <p>Cardiomyopathy</p>
            </list-item>
            <list-item>
              <p>Hypogonadism</p>
            </list-item>
            <list-item>
              <p>Arthritis (especially involving the metacarpophalangeal joints)</p>
            </list-item>
            <list-item>
              <p>Progressive increase in skin pigmentation</p>
            </list-item>
          </list>
          <p><bold>Biochemical evidence</bold> of iron overload demonstrating elevated serum transferrin-iron saturation (TS) and elevated serum ferritin concentration.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Transferrin-iron saturation (TS)</bold> is an early and reliable indicator of risk for iron overload in <italic toggle="yes">HFE</italic>-HH; the TS is not age-related in adults and does not correlate with the presence or absence of clinical findings.</p>
            </list-item>
            <list-item>
              <p>Approximately 80% of individuals with <italic toggle="yes">HFE</italic>-HH have had a fasting serum transferrin-iron saturation of at least 60% (men) or at least 50% (women) on two or more occasions in the absence of other known causes of elevated transferrin-iron saturation.</p>
            </list-item>
            <list-item>
              <p><bold>Serum ferritin concentration</bold> generally increases progressively over time in individuals with untreated clinical <italic toggle="yes">HFE</italic>-HH; however, an elevated serum ferritin concentration alone is not specific for iron overload as it is an acute phase reactant and may be caused by inflammatory or neoplastic disorders (especially when the serum TS is normal). Commonly accepted ferritin values for the upper limit of normal (from the HEIRS study) are &#x0003c;300 ng/mL in males and &#x0003c;200 ng/mL in females [<xref ref-type="bibr" rid="hemochromatosis.REF.adams.2005.1769">Adams et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>No &#x0201c;typical&#x0201d; range for ferritin values for persons with <italic toggle="yes">HFE</italic>-HH has been defined: it may range from normal to several thousand.</p>
            </list-item>
          </list>
          <p>An algorithm for screening for <italic toggle="yes">HFE</italic>-associated hemochromatosis has been developed (see <xref ref-type="fig" rid="hemochromatosis.F1">Figure 1</xref>).</p>
        </sec>
        <sec id="hemochromatosis.Establishing_the_Diagnos">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of <italic toggle="yes">HFE</italic>-HH is established in a proband with the identification of biallelic pathogenic variants in <italic toggle="yes">HFE</italic> (see <xref ref-type="table" rid="hemochromatosis.T.summary_of_molecular_g">Table 1</xref>).</p>
          <p><bold>Molecular testing approaches</bold> can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Targeted analysis for the <xref ref-type="table" rid="hemochromatosis.T.selected_hfe_pathogeni">p.Cys282Tyr</xref> and <xref ref-type="table" rid="hemochromatosis.T.selected_hfe_pathogeni">p.His63Asp</xref>
<italic toggle="yes">HFE</italic> pathogenic variants;</p>
            </list-item>
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">HFE</italic> followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.Note: Full <italic toggle="yes">HFE</italic> gene deletion has been found to be the most common pathogenic variant in the Sardinian population [<xref ref-type="bibr" rid="hemochromatosis.REF.le_gac.2010.685">Le Gac et al 2010</xref>].</p>
            </list-item>
          </list>
          <table-wrap id="hemochromatosis.T.summary_of_molecular_g" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">HFE</italic>-HH</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_2">Test Method</th>
                  <th id="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3" id="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Genotype</th>
                  <th headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3" id="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Individuals with HH&#x000a0;<sup>2,&#x000a0;3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">HFE</italic>
                  </td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_2" rowspan="3" valign="middle" align="left" colspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">p.[Cys282Tyr]+[Cys282Tyr]</td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~60%-90%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">p.[Cys282Tyr]+[His63Asp]</td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">3%-8%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">p.[His63Asp]+[His63Asp]</td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~1%&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Other&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Rare&#x000a0;<sup>8</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">Other</td>
                  <td headers="hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_1_3 hd_h_hemochromatosis.T.summary_of_molecular_g_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Rare&#x000a0;<sup>10</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hemochromatosis.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="hemochromatosis" object-id="hemochromatosis.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="hemochromatosis.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="hemochromatosis.TF.1.2">
                <label>2. </label>
                <p>In populations of European origin [<xref ref-type="bibr" rid="hemochromatosis.REF.ramrakhiani.1998.41">Ramrakhiani &#x00026; Bacon 1998</xref>]</p>
              </fn>
              <fn id="hemochromatosis.TF.1.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="hemochromatosis.REF.morrison.2003.627">Morrison et al [2003]</xref>
                </p>
              </fn>
              <fn id="hemochromatosis.TF.1.4">
                <label>4. </label>
                <p>Typically includes the <xref ref-type="table" rid="hemochromatosis.T.selected_hfe_pathogeni">p.Cys282Tyr</xref> and <xref ref-type="table" rid="hemochromatosis.T.selected_hfe_pathogeni">p.His63Asp</xref> pathogenic variants. Note: Pathogenic variants included in a panel may vary by laboratory.</p>
              </fn>
              <fn id="hemochromatosis.TF.1.5">
                <label>5. </label>
                <p>
                  <xref ref-type="bibr" rid="hemochromatosis.REF.feder.1996.399">Feder et al [1996]</xref>
                </p>
              </fn>
              <fn id="hemochromatosis.TF.1.6">
                <label>6. </label>
                <p>Although biochemically defined abnormalities may be present in p.[His63Asp]+[His63Asp], characteristic clinical manifestations are rare [<xref ref-type="bibr" rid="hemochromatosis.REF.gochee.2002.646">Gochee et al 2002</xref>].</p>
              </fn>
              <fn id="hemochromatosis.TF.1.7">
                <label>7. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="hemochromatosis.TF.1.8">
                <label>8. </label>
                <p>Typically compound heterozygous for the p.Cys282Tyr pathogenic variant and a second rare pathogenic variant. A number of private pathogenic variants have been described, including <xref ref-type="table" rid="hemochromatosis.T.selected_hfe_pathogeni">p.Glu168Ter</xref> and <xref ref-type="table" rid="hemochromatosis.T.selected_hfe_pathogeni">p.Trp169Ter</xref>, found with an allele frequency respectively of 25% and 8.4% in individuals with hemochromatosis in two northern regions of Italy [<xref ref-type="bibr" rid="hemochromatosis.REF.piperno.2000.441">Piperno et al 2000</xref>].</p>
              </fn>
              <fn id="hemochromatosis.TF.1.9">
                <label>9. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="hemochromatosis.TF.1.10">
                <label>10. </label>
                <p>Full <italic toggle="yes">HFE</italic> gene deletion is the most common cause of hemochromatosis in the Sardinian population [<xref ref-type="bibr" rid="hemochromatosis.REF.le_gac.2010.685">Le Gac et al 2010</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="hemochromatosis.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hemochromatosis.Clinical_Description">
          <title>Clinical Description</title>
          <p>Three phenotypes of <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis <italic toggle="yes">(HFE</italic>-HH) are now recognized:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical <italic toggle="yes">HFE</italic>-HH (individuals with end-organ damage [e.g., advanced cirrhosis, cardiac failure, skin pigment changes, or diabetes] secondary to iron storage)</p>
            </list-item>
            <list-item>
              <p>Biochemical <italic toggle="yes">HFE</italic>-HH (individuals with evidence of iron overload as determined by transferrin-iron saturation and serum ferritin concentration only)</p>
            </list-item>
            <list-item>
              <p>Non-expressing p.Cys282Tyr homozygotes (p.Cys282Tyr homozygotes without clinical or biochemical evidence of iron overload [i.e., normal serum ferritin concentration])</p>
            </list-item>
          </list>
          <p>Individuals with <italic toggle="yes">HFE</italic>-HH may be identified because of signs and symptoms related to iron overload (i.e., clinical <italic toggle="yes">HFE</italic>-HH); however, most frequently they are identified before symptoms develop, either through detection of abnormal iron-related studies (i.e., biochemical <italic toggle="yes">HFE</italic>-HH) or by molecular genetic testing used in their evaluation as family members at risk for <italic toggle="yes">HFE</italic>-HH (non-expressing p.Cys282Tyr homozygotes).</p>
          <p><bold>The difference between clinical <italic toggle="yes">HFE</italic>-HH and biochemical <italic toggle="yes">HFE</italic>-HH</bold> must be understood in the interpretation of population studies evaluating morbidity related to HH. Several large-scale screening studies in the general population have demonstrated that most individuals homozygous for the p.Cys282Tyr pathogenic variant do not have clinical <italic toggle="yes">HFE</italic>-HH; however, a significant proportion of individuals with this genotype (especially males) have biochemical <italic toggle="yes">HFE</italic>-HH.</p>
          <p>
            <bold>Factors influencing disease manifestation</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Gender.</bold> Reports suggest that of p.Cys282Tyr homozygotes, a higher proportion of males than females (28% vs 1%) have definite disease manifestation of hemochromatosis [<xref ref-type="bibr" rid="hemochromatosis.REF.allen.2008.221">Allen et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Detection through screening.</bold> When identified through iron studies or screening of at-risk family members, 75%-90% of individuals with <italic toggle="yes">HFE</italic>-HH are asymptomatic.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Normal serum ferritin concentration at diagnosis is usually associated with lack of symptom development [<xref ref-type="bibr" rid="hemochromatosis.REF.yamashita.2003.388">Yamashita &#x00026; Adams 2003</xref>].</p>
                </list-item>
                <list-item>
                  <p>Clinical disease appears to be more common among at-risk sibs of clinically affected individuals.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <sec id="hemochromatosis.Clinical_HFEHH">
            <title>Clinical <italic toggle="yes">HFE</italic>-HH</title>
            <p>Individuals with clinical <italic toggle="yes">HFE</italic>-HH have inappropriately high absorption of iron from a normal diet by the gastrointestinal mucosa, resulting in excessive parenchymal storage of iron, which may result in damage in a number of end-organs and, potentially, organ failure.</p>
            <p><bold>Age of onset.</bold> Symptoms related to iron overload usually appear between age 40 and 60 years in males and after menopause in females. Occasionally, <italic toggle="yes">HFE</italic>-HH manifests at an earlier age, but hepatic fibrosis or cirrhosis is rare before age 40 years.</p>
            <p><bold>Early signs.</bold> Often the first signs of clinical <italic toggle="yes">HFE</italic>-HH are arthropathy (joint stiffness and pain) involving the metacarpophalangeal joints, progressive increase in skin pigmentation resulting from deposits of melanin and iron, diabetes mellitus resulting from pancreatic iron deposits, and cardiomyopathy resulting from cardiac parenchymal iron stores. Hepatomegaly may or may not be present early in the disease; however, asymptomatic individuals can occasionally have hepatomegaly on physical examination. Males may have impotence from pituitary dysfunction. In women hypogonodism leads to diminished libido and possibly infertility. Abdominal pain, weakness, lethargy, and weight loss are common, but nonspecific, findings.</p>
            <p>Alcohol consumption worsens the symptoms in <italic toggle="yes">HFE</italic>-HH [<xref ref-type="bibr" rid="hemochromatosis.REF.scotet.2003.129">Scotet et al 2003</xref>]. Moderate to heavy alcohol consumption increases the risk of cirrhosis by 10% [<xref ref-type="bibr" rid="hemochromatosis.REF.fletcher.2002.281">Fletcher et al 2002</xref>].</p>
            <p><bold>With progression of the disease,</bold> liver cirrhosis may develop and be complicated by portal hypertension, hepatocellular carcinoma, and end-stage liver disease [<xref ref-type="bibr" rid="hemochromatosis.REF.kowdley.2005.494">Kowdley et al 2005</xref>]. The HEIRS study found an odds ratio of 3.3 for liver disease among men homozygous for p.Cys282Tyr [<xref ref-type="bibr" rid="hemochromatosis.REF.adams.2005.1769">Adams et al 2005</xref>]. In addition, as stated above, cirrhosis is much more common among p.Cys282Tyr homozygotes who consume more than 60 g of alcohol per day compared to those who drink less [<xref ref-type="bibr" rid="hemochromatosis.REF.fletcher.2002.281">Fletcher et al 2002</xref>].</p>
            <p>By the time cirrhosis or liver failure is recognized, approximately 50% of individuals have diabetes mellitus and 15% have congestive heart failure or arrhythmias.</p>
            <p><bold>Life expectancy.</bold> Individuals diagnosed and treated prior to the development of cirrhosis have normal life expectancy; those identified after the development of cirrhosis have a decreased life expectancy even with iron depletion therapy [<xref ref-type="bibr" rid="hemochromatosis.REF.adams.2005.1769">Adams et al 2005</xref>] primarily due to the development of hepatocellular cancer.</p>
            <p><bold>Prognosis.</bold> Individuals with cirrhosis who are treated have a better outcome than those who are not; however, treatment does not eliminate the 10%-30% risk for hepatocellular carcinoma (HCC) and cholangiocarcinoma years after successful iron depletion in those subjects with cirrhosis.</p>
            <p>Failure to deplete iron stores after 18 months of treatment is a poor prognostic sign. With iron depletion, dysfunction of some affected organs (liver and heart) can improve; however, endocrine abnormalities and arthropathy improve in only 20% of those treated.</p>
            <p>Death in individuals with clinical <italic toggle="yes">HFE</italic>-HH is usually caused by liver failure, cancer, congestive heart failure, or arrhythmia.</p>
          </sec>
          <sec id="hemochromatosis.Biochemical_HFEHH">
            <title>Biochemical <italic toggle="yes">HFE</italic>-HH</title>
            <p>Controversy exists among experts as to whether individuals who have biochemical <italic toggle="yes">HFE</italic>-HH in the absence of clinical <italic toggle="yes">HFE</italic>-HH are at increased risk for development of complications of iron overload and whether they are candidates for phlebotomy treatment (see <xref ref-type="sec" rid="hemochromatosis.Management">Management</xref>).</p>
            <p><bold>Ferritin levels at diagnosis.</bold> Bardou-Jacquet and colleagues concluded that <italic toggle="yes">HFE</italic> Cys282Tyr homozygotes with a serum ferritin at diagnosis between the upper limit of normal and 1000 &#x003bc;g/L have reduced mortality compared to the general population owing to phlebotomy therapy [<xref ref-type="bibr" rid="hemochromatosis.REF.bardoujacquet.2015a.283">Bardou-Jacquet et al 2015a</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.bardoujacquet.2015b.682">Bardou-Jacquet et al 2015b</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.bardoujacquet.2015c">Bardou-Jacquet et al 2015c</xref>]. Conversely, an Australian consortium believes the benefits of phlebotomy for p.Cys282Tyr homozygotes with mildly elevated serum ferritin remains unproven without a randomized study [<xref ref-type="bibr" rid="hemochromatosis.REF.delatycki.2015.282">Delatycki et al 2015</xref>].</p>
            <p><bold>Prospective follow up</bold> of a few individuals in some studies has been inconclusive as to whether iron overload is progressive. The evidence at present suggests that although serum ferritin concentration may rise in these individuals over time, end-organ damage is uncommon but is more frequently observed in men homozygous for p.Cys282Tyr than females homozygous for p.Cys282Tyr [see <xref ref-type="bibr" rid="hemochromatosis.REF.yamashita.2003.388">Yamashita &#x00026; Adams 2003</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.andersen.2004.2914">Andersen et al 2004</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.olynyk.2004.309">Olynyk et al 2004</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.allen.2008.221">Allen et al 2008</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.gurrin.2008.1945">Gurrin et al 2008</xref>].</p>
            <p><bold>Modifying factors.</bold> It has been assumed for many years that additional modifying factors or genes are required for expression of hemochromatosis in p.Cys282Tyr homozygotes. An international consortium has recently identified a modifying gene known as <italic toggle="yes">GNPAT</italic> which is over-expressed in men homozygous for p.Cys282Tyr expressing severe iron overload [<xref ref-type="bibr" rid="hemochromatosis.REF.mclaren.2015.429">McLaren et al 2015</xref>].</p>
          </sec>
          <sec id="hemochromatosis.NonExpressing_p_Cys282Ty">
            <title>Non-Expressing p.Cys282Tyr Homozygotes</title>
            <p>Three longitudinal population-based screening studies showed that 38%-50% of p.Cys282Tyr homozygotes may develop iron overload (i.e., elevated serum ferritin concentration) and 10%-33% may eventually develop hemochromatosis-related symptoms [<xref ref-type="bibr" rid="hemochromatosis.REF.whitlock.2006.209">Whitlock et al 2006</xref>] (i.e., nonspecific symptoms that may include fatigue and arthralgia) or end-organ damage (e.g., diabetes mellitus, cirrhosis, and/or cardiomyopathy). The vast majority developing end-organ damage are male [<xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver 2010</xref>].</p>
            <p>Therefore, while &#x0201c;non-expressing homozygotes&#x0201d; are unlikely to develop end-organ damage over time, a substantial proportion of males who have biallelic p.Cys282Tyr variants may develop progressive iron overload or symptoms of iron overload [<xref ref-type="bibr" rid="hemochromatosis.REF.yamashita.2003.388">Yamashita &#x00026; Adams 2003</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.gurrin.2008.1945">Gurrin et al 2008</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.gurrin.2009.94">Gurrin et al 2009</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.allen.2010.925">Allen et al 2010</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.gan.2011.293">Gan et al 2011</xref>].</p>
          </sec>
          <sec id="hemochromatosis.Heterozygotes">
            <title>Heterozygotes</title>
            <p>Some individuals who are heterozygous for either the <italic toggle="yes">HFE</italic> p.Cys282Tyr or p.His63Asp pathogenic variant tend to have elevated serum transferrin-iron saturation (TS) and ferritin concentrations that exceed normal; however, they do not develop complications of iron overload [<xref ref-type="bibr" rid="hemochromatosis.REF.bulaj.1996.1799">Bulaj et al 1996</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.allen.2008.221">Allen et al 2008</xref>].</p>
            <p>Although a threshold serum TS of 45% may be more sensitive than the higher values used in the past for detecting <italic toggle="yes">HFE</italic>-HH, it may identify heterozygotes who are not at risk of developing clinical findings [<xref ref-type="bibr" rid="hemochromatosis.REF.mclaren.1998.543">McLaren et al 1998</xref>].</p>
            <p>In the large study in Danish men, <xref ref-type="bibr" rid="hemochromatosis.REF.pedersen.2009.775">Pedersen &#x00026; Milman [2009]</xref> showed that:</p>
            <list list-type="bullet">
              <list-item>
                <p>Among p.Cys282Tyr/wild type (wt) heterozygotes, 9% had elevated serum TS (&#x02265;50%), 9% had elevated ferritin (&#x02265;300 ng/mL), and 1.2% had elevation of both serum TS and ferritin.</p>
              </list-item>
              <list-item>
                <p>Among p.His63Asp/wt heterozygotes, 8% had elevated serum TS, 12% had elevated ferritin, and 2% had elevation of both serum TS and ferritin.</p>
              </list-item>
            </list>
            <p>Note: The abnormalities in iron studies observed in p.Cys282Tyr heterozygotes do not necessarily reflect a hemochromatosis-associated phenotype.</p>
          </sec>
        </sec>
        <sec id="hemochromatosis.GenotypePhenotype_Correl">
          <title>Genotype-Phenotype Correlations</title>
          <p>Homozygotes for p.Cys282Tyr are at greater risk for iron overload than p.Cys282Tyr/p.His63Asp compound heterozygotes.</p>
        </sec>
        <sec id="hemochromatosis.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance in <italic toggle="yes">HFE</italic>-HH refers to the percentage of adults (males and females separately) homozygous or compound heterozygous for <italic toggle="yes">HFE</italic> pathogenic variants who exhibit either clinical <italic toggle="yes">HFE</italic>-HH or biochemical <italic toggle="yes">HFE</italic>-HH:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>p.Cys282Tyr homozygotes.</bold> Penetrance for biochemically defined iron overload among p.Cys282Tyr homozygotes is relatively high, but not 100%. In contrast, accumulating data suggest that penetrance for clinically defined iron overload is quite low. In the absence of unbiased data, penetrance of clinical endpoints of iron overload cannot yet be determined for individuals homozygous for p.Cys282Tyr; however, penetrance was as low as 2% in the large study by <xref ref-type="bibr" rid="hemochromatosis.REF.beutler.2002.211">Beutler et al [2002]</xref>. Currently, no test can predict whether an individual homozygous for p.Cys282Tyr will develop clinical <italic toggle="yes">HFE</italic>-HH.</p>
            </list-item>
            <list-item>
              <p><bold>p.Cys282Tyr/p.His63Asp compound heterozygotes.</bold> The penetrance for this genotype is low: only approximately 0.5%-2.0% of such individuals develop clinical evidence of iron overload [<xref ref-type="bibr" rid="hemochromatosis.REF.gurrin.2009.94">Gurrin et al 2009</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>Many p.Cys282Tyr/p.His63Asp compound heterozygotes who develop clinical evidence of iron overload appear to have a complicating factor (e.g., fatty liver, viral hepatitis) that leads to iron overload.</p>
                </list-item>
                <list-item>
                  <p>Male p.Cys282Tyr/p.His63Asp compound heterozygotes also were more likely to report a history of liver disease in the HEIRS study (odds ratio 1.7 p=0.05) [<xref ref-type="bibr" rid="hemochromatosis.REF.adams.2005.1769">Adams et al 2005</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>p.His63Asp homozygotes.</bold> The penetrance for this genotype is even lower than the penetrance of the p.[Cys282Tyr]+[His63Asp] genotype. Although biochemically defined abnormalities may be present, characteristic clinical manifestations are rare [<xref ref-type="bibr" rid="hemochromatosis.REF.gochee.2002.646">Gochee et al 2002</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemochromatosis.Nomenclature">
          <title>Nomenclature</title>
          <p><italic toggle="yes">HFE</italic>-HH has been variably described in the past as hereditary hemochromatosis, primary hemochromatosis, genetic hemochromatosis, and "bronze diabetes."</p>
          <p>More recently, after the identification of other forms of iron overload associated with pathogenic variants in other iron-related genes, <italic toggle="yes">HFE</italic>-HH has been described as <italic toggle="yes">HFE</italic>-hemochromatosis or type 1 hemochromatosis.</p>
        </sec>
        <sec id="hemochromatosis.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of individuals homozygous for the variant p.Cys282Tyr is approximately 3:1000 to 5:1000, or 1:200 to 1:400 [<xref ref-type="bibr" rid="hemochromatosis.REF.adams.2005.1769">Adams et al 2005</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>The frequency of homozygotes among African Americans is rare (1:7000), with 2.3% of that population being heterozygotes.</p>
            </list-item>
            <list-item>
              <p>Homozygosity for the p.Cys282Tyr variant is extremely rare among Asians; heterozygotes have an estimated frequency of 1:1000.</p>
            </list-item>
            <list-item>
              <p>Hispanics have homozygote and heterozygote frequencies of 0.027% and 3.0%, respectively.</p>
            </list-item>
          </list>
          <p>The p.His63Asp variant rarely causes clinical problems in the homozygous or compound heterozygous (p.[Cys282Tyr]+[His63Asp]) state and is relatively common in the heterozygous state in most populations (northern Europeans: 25%; Hispanics: 18%; African Americans: 6%; Asians: 8.5%).</p>
          <p>Considering the high frequency of heterozygotes for the p.Cys282Tyr and p.His63Asp alleles, approximately one third of the northern European population is heterozygous for either one or the other of these two variant alleles.</p>
        </sec>
      </sec>
      <sec id="hemochromatosis.Genetically_Related_Alle">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Numerous studies have examined the relationship between <italic toggle="yes">HFE</italic> pathogenic variants and other diseases; however, no phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">HFE</italic> [<xref ref-type="bibr" rid="hemochromatosis.REF.dubois.2004.1">DuBois &#x00026; Kowdley 2004</xref>].</p>
      </sec>
      <sec id="hemochromatosis.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis <italic toggle="yes">(HFE</italic>-HH) (sometimes called type 1 HH) needs to be distinguished from several much rarer primary iron overload disorders as well as from secondary iron overload disorders.</p>
        <p><bold>Primary overload disorders</bold> are characterized by increased absorption of iron from a normal diet. The following first two forms of hemochromatosis result from hepcidin deficiency. Thus the clinical manifestations are identical to p.Cys282Tyr hemochromatosis but more severe:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="jh" document-type="chapter"><bold>Juvenile hereditary hemochromatosis</bold></related-object> (sometimes called type 2 HH) has an earlier age of onset and more severe clinical manifestations than type 1 HH. Hepatocellular cancer has not been reported, possibly because of the short life span in this disorder. Pathogenic variants have been identified in two genes, giving rise to two clinically indistinguishable "subtypes": type 2A, caused by pathogenic variants in <italic toggle="yes">HJV</italic> encoding hemojuvelin; and type 2B, caused by pathogenic variants in <italic toggle="yes">HAMP</italic>. Inheritance is autosomal recessive [<xref ref-type="bibr" rid="hemochromatosis.REF.roetto.1999.1388">Roetto et al 1999</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.camaschella.2000.14">Camaschella et al 2000</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.de_gobbi.2002.973">De Gobbi et al 2002</xref>].</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="tfr2" document-type="chapter"><bold><italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis</bold></related-object> (sometimes called type 3 HH) has a similar presentation to <italic toggle="yes">HFE</italic>-HH. Age of onset is earlier and progression is slower than in juvenile HH. It is caused by pathogenic variants in <italic toggle="yes">TFR2</italic>, which encodes transferrin receptor 2.<italic toggle="yes">TFR2</italic>-related hereditary hemochromatosis is rare; it has primarily been reported in Italy. Inheritance is autosomal recessive [<xref ref-type="bibr" rid="hemochromatosis.REF.mattman.2002.1075">Mattman et al 2002</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Ferroportin (<italic toggle="yes">SLC40A1</italic>)-related iron overload</bold> (ferroportin disease, type 4 hemochromatosis, HFE4) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/606069">606069</ext-link>) is also a disorder of iron overload, but unlike juvenile and <italic toggle="yes">HFE</italic>-HH, macrophages are iron laden. Onset is late and, in contrast to all other varieties of hemochromatosis, iron storage affects reticuloendothelial rather than parenchymal cells [<xref ref-type="bibr" rid="hemochromatosis.REF.montosi.2001.619">Montosi et al 2001</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.njajou.2001.213">Njajou et al 2001</xref>]. HFE4 presents in adulthood. It is caused by pathogenic variants in <italic toggle="yes">SLC40A1</italic>, which encodes ferroportin. Inheritance is autosomal dominant [<xref ref-type="bibr" rid="hemochromatosis.REF.pietrangelo.2004.131">Pietrangelo 2004</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>African iron overload</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/601195">601195</ext-link>) results from a predisposition to iron overload that is exacerbated by excessive intake of dietary iron. It is particularly prevalent among Africans who drink a traditional beer brewed in non-galvanized steel drums. Mutation of other yet-to-be-defined iron-related genes predisposes to this condition. A specific pathogenic variant (p.Gln248His) in <italic toggle="yes">SLC40A1</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_014585.5">NM_014585.5</ext-link>) encoding ferroportin has been associated with a tendency to iron overload in Africans and African Americans [<xref ref-type="bibr" rid="hemochromatosis.REF.mcnamara.2005.1855">McNamara et al 2005</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.rivers.2007.247">Rivers et al 2007</xref>]. Another probable pathogenic variant (p.Asp270Val) in <italic toggle="yes">SLC40A1</italic> was discovered in an African American man with mild iron overload [<xref ref-type="bibr" rid="hemochromatosis.REF.lee.2012.28">Lee et al 2012</xref>].</p>
          </list-item>
          <list-item>
            <p><bold>Neonatal hemochromatosis</bold> is a severe, often fatal iron overload syndrome that usually presents at birth. Iron overload occurs in utero. Inheritance is unknown, but autosomal recessive and mitochondrial inheritance have been postulated. No locus has been identified. A recent paper suggests that pathogenic variants in <italic toggle="yes">DGUOK</italic>, the gene which encodes deoxyguanosine kinase, may lead to a phenotype resembling this condition [<xref ref-type="bibr" rid="hemochromatosis.REF.pronicka.2011.61">Pronicka et al 2011</xref>]. See <related-object link-type="booklink" source-id="gene" document-id="dguok-mtddepl" document-type="chapter"><italic toggle="yes">DGUOK</italic>-Related Mitochondrial DNA Depletion Syndrome, Hepatocerebral Form</related-object>.</p>
          </list-item>
        </list>
        <p>
          <bold>Secondary iron overload disorders</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>Liver diseases associated with parenchymal liver disease include conditions such as alcoholic liver disease, acute viral hepatitis or chronic hepatitis C, neoplasms, <related-object link-type="booklink" source-id="gene" document-id="porphyria-ct" document-type="chapter">porphyria cutanea tarda</related-object>, and inflammatory disorders, such as rheumatoid arthritis.</p>
          </list-item>
          <list-item>
            <p>A very common liver disease, nonalcoholic fatty liver disease (NAFLD) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613282">613282</ext-link>) may frequently lead to elevated serum ferritin level and may be associated with increased hepatic iron deposition [<xref ref-type="bibr" rid="hemochromatosis.REF.nelson.2011.448">Nelson et al 2011</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.kowdley.2012.77">Kowdley et al 2012</xref>].</p>
          </list-item>
          <list-item>
            <p>Iron overload can result from ingested iron in foods, cooking ware, and medicines, as well as parenteral iron from iron injections or transfusions for a chronic anemia (e.g., <related-object link-type="booklink" source-id="gene" document-id="b-thal" document-type="chapter">beta-thalassemia</related-object>, <related-object link-type="booklink" source-id="gene" document-id="sickle" document-type="chapter">sickle cell disease</related-object>).</p>
          </list-item>
        </list>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS235200">Hemochromatosis: OMIM Phenotypic Series</ext-link>, to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="hemochromatosis.Management">
        <title>Management</title>
        <p>The American Association for the Study of Liver Disease (AASLD) has published practice guidelines for diagnosis and management of hemochromatosis [<xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">full text</ext-link>). The European Association for the Study of the Liver (EASL) published Clinical Practice Guidelines on the Management of hemochromatosis [<xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver 2010</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">full text</ext-link>).</p>
        <sec id="hemochromatosis.Evaluations_Following_In">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis <italic toggle="yes">(HFE</italic>-HH), the following evaluations are recommended at initial diagnosis:</p>
          <list list-type="bullet">
            <list-item>
              <p>Serum ferritin concentration to establish disease status and prognosis (see <xref ref-type="fig" rid="hemochromatosis.F2">Figure 2</xref>)</p>
            </list-item>
            <list-item>
              <p>For p.Cys282Tyr homozygotes:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Liver biopsy remains the gold standard for establishing or excluding cirrhosis.</p>
                </list-item>
                <list-item>
                  <p>Liver biopsy is recommended for those with serum ferritin &#x0003e;1,000 ng/mL or elevated AST and ALT to evaluate for advanced hepatic fibrosis [<xref ref-type="bibr" rid="hemochromatosis.REF.morrison.2003.627">Morrison et al 2003</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>].</p>
                </list-item>
                <list-item>
                  <p>Liver biopsy is not recommended for those with serum ferritin concentration &#x0003c;1,000 ng/mL and normal ALT and AST because their risk for advanced hepatic fibrosis is low [<xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>MRI to estimate parenchymal iron content by utilizing the paramagnetic properties of iron:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A specialized MRI technique with excellent sensitivity for estimation of hepatic iron concentration was approved by the FDA for clinical use [<xref ref-type="bibr" rid="hemochromatosis.REF.st_pierre.2005.855">St Pierre et al 2005</xref>]. This method of quantitative MRI accurately measures liver iron within a sufficiently wide liver iron concentration range. Compared with liver biopsy, MRI-R<sub>2</sub> is noninvasive and significantly reduces biopsy sampling error [<xref ref-type="bibr" rid="hemochromatosis.REF.fischer.2009.215">Fischer &#x00026; Harmatz 2009</xref>]. In addition, T<sub>2</sub>* MRI measurement of liver iron is now widely available [<xref ref-type="bibr" rid="hemochromatosis.REF.brittenham.2003.15">Brittenham et al 2003</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.cheong.2005.448">Cheong et al 2005</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.ptaszek.2005.689">Ptaszek et al 2005</xref>].</p>
                </list-item>
                <list-item>
                  <p>Cardiac iron concentration can also be monitored using similar techniques and may be of prognostic value [<xref ref-type="bibr" rid="hemochromatosis.REF.fischer.2009.215">Fischer &#x00026; Harmatz 2009</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.ramazzotti.2009.62">Ramazzotti et al 2009</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Biomagnetic liver susceptometry (BLS) to estimate liver iron by measuring the change in magnetic flux as a hemochromatosis patient moves through a stable magnetic field, generating a voltage in the SQUID sensor [<xref ref-type="bibr" rid="hemochromatosis.REF.fischer.2009.215">Fischer &#x00026; Harmatz 2009</xref>]. As BLS is not widely available it is not included in diagnosis or management guidelines for hemochromatosis.</p>
            </list-item>
            <list-item>
              <p>Consultation with a medical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemochromatosis.Treatment_of_Manifestati">
          <title>Treatment of Manifestations</title>
          <p>The American Association for the Study of Liver Disease (AASLD) has published practice guidelines for diagnosis and management of hemochromatosis [<xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">full text</ext-link>). The European Association for the Study of the Liver (EASL) published Clinical Practice Guidelines on the Management of hemochromatosis [<xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver 2010</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">full text</ext-link>).</p>
          <sec id="hemochromatosis.Clinical_HFEHH_1">
            <title>Clinical <italic toggle="yes">HFE</italic>-HH</title>
            <p><bold>Therapeutic phlebotomy</bold> is indicated in the presence of symptoms of iron overload or evidence of end-organ damage (e.g., advanced cirrhosis, cardiac failure, skin pigment changes, or diabetes):</p>
            <list list-type="bullet">
              <list-item>
                <p>Periodic phlebotomy is a simple, inexpensive, safe, and effective treatment.</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Each unit of blood (400-500 mL) with a hematocrit of 40% contains approximately 160-200 mg of iron.</p>
                  </list-item>
                  <list-item>
                    <p>Each mL of packed red blood cells contains 1 mg of iron.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>The usual therapy is removal of the excess iron by weekly phlebotomy (i.e., removal of a unit of blood) until the serum ferritin concentration is 50 ng/mL or lower. Twice-weekly phlebotomy may be occasionally useful to accelerate iron depletion.</p>
              </list-item>
              <list-item>
                <p>Weekly phlebotomy is carried out until the hematocrit is 75% of the baseline hematocrit.</p>
              </list-item>
              <list-item>
                <p>At this point, if the serum ferritin concentration is &#x02265;50 ng/mL despite a significant reduction in hematocrit, the interval at which phlebotomy is performed needs to be spaced further apart. Once the serum ferritin concentration is &#x02264;100 ng/mL, serum ferritin concentration should be quantified in all affected individuals after each additional one or two treatments [<xref ref-type="bibr" rid="hemochromatosis.REF.barton.1998.932">Barton et al 1998</xref>].</p>
              </list-item>
              <list-item>
                <p>The serum ferritin concentration is the most reliable and inexpensive way to monitor therapeutic phlebotomy.</p>
              </list-item>
              <list-item>
                <p>Maintenance therapy is aimed at maintaining serum ferritin concentration &#x0003c;50 ng/mL and transferrin-iron saturation &#x0003c;50%. On average, men require removal of twice as many units of blood as women. Subsequent phlebotomies to prevent reaccumulation of iron can be carried out approximately every three to four months for men and once or twice a year for women.</p>
              </list-item>
              <list-item>
                <p>Iron chelation therapy is not recommended unless an individual has an elevated serum ferritin concentration and concomitant anemia that makes therapeutic phlebotomy impossible. However, this is uncommon in individuals with <italic toggle="yes">HFE</italic>-HH.</p>
              </list-item>
              <list-item>
                <p>Therapeutic phlebotomy improves fibrosis except in cases of cirrhosis [<xref ref-type="bibr" rid="hemochromatosis.REF.powell.2006.294">Powell et al 2006</xref>].</p>
              </list-item>
            </list>
            <p><bold>Orthotopic liver transplantation</bold> is the only treatment for end-stage liver disease from decompensated cirrhosis. However, the post-transplant survival among untreated individuals with <italic toggle="yes">HFE</italic>-HH is poor [<xref ref-type="bibr" rid="hemochromatosis.REF.crawford.2004.1655">Crawford et al 2004</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.kowdley.2005.494">Kowdley et al 2005</xref>]. Although one study suggested that outcomes may have improved, this report did not enroll persons with documented <italic toggle="yes">HFE</italic>-HH but rather used a database [<xref ref-type="bibr" rid="hemochromatosis.REF.yu.2007.489">Yu &#x00026; Ioannou 2007</xref>].</p>
          </sec>
          <sec id="hemochromatosis.Biochemical_HFEHH_1">
            <title>Biochemical <italic toggle="yes">HFE</italic>-HH</title>
            <p>Both the EASL and AASLD guidelines recommend therapeutic phlebotomy for persons with biochemical <italic toggle="yes">HFE</italic>-HH (i.e., those who have increased body iron stores in the absence of clinical evidence of iron overload). See <xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver [2010]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">full text</ext-link>) and <xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al [2011]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">full text</ext-link>). The exact serum ferritin concentration at which therapeutic phlebotomy should be initiated is not clear, the European Association for Study of Liver suggests performing phlebotomy once serum ferritin concentration is higher than 500 ng/mL.</p>
          </sec>
          <sec id="hemochromatosis.NonExpressing_p_Cys282Ty_1">
            <title>Non-Expressing p.Cys282Tyr Homozygotes</title>
            <p>These individuals do not have iron overload and thus do not need phlebotomy.</p>
          </sec>
        </sec>
        <sec id="hemochromatosis.Prevention_of_Primary_Ma">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="hemochromatosis.Treatment_of_Manifestati">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="hemochromatosis.Prevention_of_Secondary">
          <title>Prevention of Secondary Complications</title>
          <p>Individuals with iron overload should be advised against ingestion of shellfish or raw fish.</p>
          <p>Vaccination against hepatitis A and B is advised [<xref ref-type="bibr" rid="hemochromatosis.REF.tavill.2001.1321">Tavill 2001</xref>].</p>
        </sec>
        <sec id="hemochromatosis.Surveillance">
          <title>Surveillance</title>
          <sec id="hemochromatosis.Clinical_HFEHH_2">
            <title>Clinical HFE-HH</title>
            <p>Once the serum ferritin concentration is &#x0003c;50 ng/mL, monitor serum ferritin concentration every three to four months.</p>
            <p>It is reasonable to perform follow-up T<sub>2</sub>* MRI for assessment of cardiac iron among persons with a history of cardiac involvement or known cardiac iron deposition.</p>
            <p>Since cirrhosis is a crucial stage in the natural history of hemochromatosis, the diagnosis of cirrhosis is important because management changes. Individuals with cirrhosis should be followed regularly and screened for hepatocellular cancer (HCC) [<xref ref-type="bibr" rid="hemochromatosis.REF.tavill.2001.1321">Tavill 2001</xref>]. The AASLD Practice Guidelines recommend imaging every six months with good ultrasonography [<xref ref-type="bibr" rid="hemochromatosis.REF.sherman.2010.610">Sherman 2010</xref>]. This may be accompanied with measurement of alpha fetoprotein. Noninvasive methods that use results derived from values of serum markers such as HepaScore<sup>&#x000ae;</sup> and FibroMeter&#x02122; can also be used to assess the stage of liver fibrosis [<xref ref-type="bibr" rid="hemochromatosis.REF.mart_nez.2011.325">Mart&#x000ed;nez et al 2011</xref>].</p>
            <p>Although the gold standard for the diagnosis of cirrhosis is biopsy, FibroScan<sup>&#x000ae;</sup> has been shown to have good sensitivity and specificity for cirrhosis [<xref ref-type="bibr" rid="hemochromatosis.REF.tsochatzis.2011.650">Tsochatzis et al 2011</xref>]. FibroScan (also known as transient elastography) quantifies fibrosis with ultrasound in a non-invasive manner [<xref ref-type="bibr" rid="hemochromatosis.REF.tsochatzis.2011.650">Tsochatzis et al 2011</xref>]. The results from a meta-analysis suggested a cut-off value for diagnosis of cirrhosis of 13.01 kPa [<xref ref-type="bibr" rid="hemochromatosis.REF.friedrichrust.2008.960">Friedrich-Rust et al 2008</xref>]. Individuals with normal transient elastography (TE) values on FibroScan would not need a biopsy while individuals with intermediate or high TE values should have biopsies to confirm cirrhosis. These results should be interpreted in conjunction with clinical and biochemical parameters.</p>
            <p>Note: The AASLD Guidelines recommend that individuals with cirrhosis undergo surveillance regardless of whether or not they have been iron depleted [<xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">full text</ext-link>).</p>
          </sec>
          <sec id="hemochromatosis.Biochemical_HFEHH_2">
            <title>Biochemical HFE-HH</title>
            <p>Begin annual measurement of serum ferritin concentration when ferritin concentration exceeds normal levels [<xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver 2010</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">full text</ext-link>).</p>
          </sec>
          <sec id="hemochromatosis.NonExpressing_p_Cys282Ty_2">
            <title>Non-Expressing p.Cys282Tyr Homozygotes</title>
            <p>Begin annual measurement of serum ferritin concentration when ferritin concentration exceeds normal levels [<xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver 2010</xref>].</p>
          </sec>
        </sec>
        <sec id="hemochromatosis.AgentsCircumstances_to_A">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medicinal iron, mineral supplements, excess vitamin C, and uncooked seafood</p>
            </list-item>
            <list-item>
              <p>Alcohol consumption in those with hepatic involvement</p>
            </list-item>
          </list>
        </sec>
        <sec id="hemochromatosis.Evaluation_of_Relatives">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to clarify the status of apparently asymptomatic adult sibs and offspring of individuals homozygous for p.Cys282Tyr in order to identify those who would benefit from prompt initiation of treatment and preventive measures.</p>
          <p>The following strategy is appropriate:</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Offer molecular genetic testing to the adult sibs of an individual homozygous for p.Cys282Tyr.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Perform iron studies (i.e., transferrin iron saturation and serum concentration of ferritin) on those sibs who are homozygous for p.Cys282Tyr.</p>
            </list-item>
            <list-item>
              <label>3</label>
              <p>Begin phlebotomy therapy if serum ferritin concentration is elevated above the upper limits of normal and if the proband has clinical <italic toggle="yes">HFE</italic>-HH. Note: Sibs of probands with clinical <italic toggle="yes">HFE</italic>-HH appear to have a higher prevalence of clinical <italic toggle="yes">HFE</italic>-HH than asymptomatic individuals detected through screening programs.</p>
            </list-item>
          </list>
          <p>Note: Genotype-based testing has been found to be cost effective in most individuals because it has excellent negative predictive value. However, genotype-based testing has a low positive predictive value because many p.Cys282Tyr homozygotes and compound heterozygotes will not express the disease [<xref ref-type="bibr" rid="hemochromatosis.REF.elserag.2000.261">El-Serag et al 2000</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.beutler.2002.211">Beutler et al 2002</xref>].</p>
          <p>See <xref ref-type="sec" rid="hemochromatosis.Related_Genetic_Counseli">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hemochromatosis.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>No guidelines exist; common practice is to withhold phlebotomy during pregnancy.</p>
        </sec>
        <sec id="hemochromatosis.Therapies_Under_Investig">
          <title>Therapies Under Investigation</title>
          <p>The oral iron chelator, deferasirox (Exjade<sup>&#x000ae;</sup>) has been studied in a Phase I/II study in patients with hemochromatosis. Final results of this trial suggest that deferasirox is effective at reducing iron burden within an acceptable safety profile [<xref ref-type="bibr" rid="hemochromatosis.REF.phatak.2010.1671">Phatak et al 2010</xref>]. It has not yet been approved for use in treating hemochromatosis.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="hemochromatosis.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hemochromatosis.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis <italic toggle="yes">(HFE</italic>-HH) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="hemochromatosis.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most parents of individuals with <italic toggle="yes">HFE</italic>-HH are heterozygotes (i.e., carriers of one <italic toggle="yes">HFE</italic> pathogenic variant).</p>
              <list list-type="bullet">
                <list-item>
                  <p>Heterozygotes do not develop iron overload but may occasionally have abnormal serum iron studies [<xref ref-type="bibr" rid="hemochromatosis.REF.bulaj.1996.1799">Bulaj et al 1996</xref>]. (See Clinical Description, <xref ref-type="sec" rid="hemochromatosis.Heterozygotes">Heterozygotes</xref>).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>On occasion, one parent has biallelic <italic toggle="yes">HFE</italic> pathogenic variants and may have clinical <italic toggle="yes">HFE</italic>-HH (i.e., presence of significant end-organ damage including advanced cirrhosis, cardiac failure, skin pigment changes, or diabetes). Thus, it is appropriate to evaluate the parents of an individual with <italic toggle="yes">HFE</italic>-HH by molecular genetic testing (for the p.Cys282Tyr and p.His63Asp pathogenic variants) or by serum iron studies (i.e., transferrin iron saturation (TS) and serum concentration of ferritin).Note: The occurrence of an autosomal recessive disorder in two generations of a family without consanguinity (called "pseudodominance") is attributed to the high carrier frequency of <italic toggle="yes">HFE</italic> pathogenic variants in persons of European origin (see <xref ref-type="sec" rid="hemochromatosis.Prevalence">Prevalence</xref>).</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>If both parents are heterozygous, each sib of an affected individual has at conception a 25% chance of inheriting both <italic toggle="yes">HFE</italic> pathogenic variants, a 50% chance of inheriting one <italic toggle="yes">HFE</italic> pathogenic variant, and a 25% chance of inheriting neither <italic toggle="yes">HFE</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>When one parent is homozygous for p.Cys282Tyr and the other parent is heterozygous for an <italic toggle="yes">HFE</italic> pathogenic variant, each sib of an individual with <italic toggle="yes">HFE</italic>-HH has a 50% chance of inheriting both <italic toggle="yes">HFE</italic> pathogenic variants and a 50% chance of inheriting one <italic toggle="yes">HFE</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Unless an individual with <italic toggle="yes">HFE</italic>-HH has children with an affected individual or a heterozygote (carrier), his/her offspring will be obligate heterozygotes for an <italic toggle="yes">HFE</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The risk that a northern European reproductive partner of an individual with <italic toggle="yes">HFE</italic>-HH is heterozygous for the p.Cys282Tyr pathogenic variant is approximately 1/9. Thus, the risk to the offspring of a proband of being homozygous for this pathogenic variant is approximately 5% (i.e., 1/9 x 1/2 = 1/18).</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of an <italic toggle="yes">HFE</italic> pathogenic variant.</p>
        </sec>
        <sec id="hemochromatosis.Carrier_Heterozygote_Det">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">HFE</italic> pathogenic variants in the family.</p>
          <p>Molecular genetic testing can be offered to the reproductive partner of a person with <italic toggle="yes">HFE</italic>-HH to determine if their offspring are at risk for <italic toggle="yes">HFE</italic>-HH.</p>
        </sec>
        <sec id="hemochromatosis.Related_Genetic_Counseli">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="hemochromatosis.Evaluation_of_Relatives">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Testing of asymptomatic individuals younger than age 18 years</bold> who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.</p>
          <p>It is appropriate to consider testing symptomatic individuals regardless of age in a family with an established diagnosis of <italic toggle="yes">HFE</italic>-HH.</p>
          <p>For more information, see also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers or affected.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hemochromatosis.Population_Screening">
          <title>Population Screening</title>
          <p>Population screening has been considered because of the high prevalence of <italic toggle="yes">HFE</italic>-HH, the lack of clinical findings early in the course of the disease, the lack of specificity of clinical findings once they appear, the low cost of diagnosis, the relatively simple and effective early treatment, and the high cost and low success rate of treatment when the diagnosis is established late. For logistical reasons, however, population screening is still not recommended.</p>
          <p><bold>Genotype-based population screening of <italic toggle="yes">HFE</italic>-HH</bold> is not recommended because penetrance appears to be low and the natural history of untreated individuals cannot be predicted. See <xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver [2010]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">full text</ext-link>) and <xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al [2011]</xref> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">full text</ext-link>).</p>
          <p><bold>Biochemical-based screening</bold> (using the serum iron markers transferrin iron saturation and serum concentration of ferritin) should be considered especially among men older than age 30 years who are of northern European descent [<xref ref-type="bibr" rid="hemochromatosis.REF.phatak.2008.270">Phatak et al 2008</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF3">European Association for the Study of the Liver 2010</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>].</p>
        </sec>
        <sec id="hemochromatosis.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>Because the <italic toggle="yes">HFE</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">HFE</italic> pathogenic variants have been identified.</p>
        </sec>
      </sec>
      <sec id="hemochromatosis.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hemochromatosis.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">HFE</italic> is approximately 13 kb in size and comprises seven exons [<xref ref-type="bibr" rid="hemochromatosis.REF.feder.1996.399">Feder et al 1996</xref>, <xref ref-type="bibr" rid="hemochromatosis.REF.albig.1998.117">Albig et al 1998</xref>]; <italic toggle="yes">HFE</italic> gives rise to at least eleven alternative transcripts encoding four to seven exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hemochromatosis" object-id="hemochromatosis.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> At least 28 distinct pathogenic variants have been reported; most are missense or nonsense. Two missense variants account for the vast majority of disease-causing alleles in the population:</p>
        <list list-type="bullet">
          <list-item>
            <p>p.Cys282Tyr removes a highly conserved cysteine residue that normally forms an intermolecular disulfide bond with beta-2-microglobulin, and thereby prevents the protein from being expressed on the cell surface.</p>
          </list-item>
          <list-item>
            <p>p.His63Asp may alter a pH-dependent intramolecular salt bridge, possibly affecting interaction of the HFE protein with the transferrin receptor.</p>
          </list-item>
        </list>
        <p>In addition, p.Ser65Cys has been seen in combination with p.Cys282Tyr in individuals with iron overload [<xref ref-type="bibr" rid="hemochromatosis.REF.bacon.2011">Bacon et al 2011</xref>]. Unlike individuals heterozygous for the common pathogenic variants, no p.Ser65Cys/wt heterozygotes had elevation of both serum TS and ferritin.</p>
        <table-wrap id="hemochromatosis.T.selected_hfe_pathogeni" position="anchor" orientation="portrait">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">HFE</italic> Pathogenic Allelic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.187C&#x0003e;G</td>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His63Asp</td>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_3" rowspan="5" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000410.3">NM_000410.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000401.1">NP_000401.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.193A&#x0003e;T</td>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser65Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.502G&#x0003e;T</td>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu168Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.506G&#x0003e;A</td>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp169Ter</td>
              </tr>
              <tr>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.845G&#x0003e;A</td>
                <td headers="hd_h_hemochromatosis.T.selected_hfe_pathogeni_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys282Tyr</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The largest predicted primary translation product is 348 amino acids, which gives rise to a mature protein of approximately 321 amino acids after cleavage of the signal sequence. The HFE protein is similar to HLA Class I molecules at the level of the primary structure [<xref ref-type="bibr" rid="hemochromatosis.REF.feder.1996.399">Feder et al 1996</xref>] and tertiary structure [<xref ref-type="bibr" rid="hemochromatosis.REF.lebr_n.1998.111">Lebr&#x000f3;n et al 1998</xref>]. The mature protein is expressed on the cell surface as a heterodimer with beta-2-microglobulin, and this interaction is necessary for normal presentation on the cell surface. The normal HFE protein binds to transferrin receptor 1 on the cell surface and may reduce cellular iron uptake; the exact means by which the HFE protein regulates iron uptake is as yet unclear [<xref ref-type="bibr" rid="hemochromatosis.REF.fleming.2004.755">Fleming et al 2004</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The p.Cys282Tyr pathogenic variant destroys a key cysteine residue that is required for disulfide bonding with beta-2-microglobulin. As a result, the HFE protein does not mature properly and becomes trapped in the endoplasmic reticulum and Golgi apparatus, leading to decreased cell-surface expression. The mechanistic basis for the phenotypic effect of other <italic toggle="yes">HFE</italic> pathogenic variants is not clear at present.</p>
      </sec>
      <sec id="hemochromatosis.References">
        <title>References</title>
        <sec id="hemochromatosis.Published_GuidelinesCons">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="hemochromatosis.Published_GuidelinesCons.reflist0">
            <ref id="hemochromatosis.REF.bacon.2011">
              <mixed-citation publication-type="webpage">Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149125/?tool=pubmed">online</ext-link>. 2011. Accessed 9-14-15.</mixed-citation>
            </ref>
            <ref id="hemochromatosis.REF2">
              <mixed-citation publication-type="webpage">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 9-14-15.</mixed-citation>
            </ref>
            <ref id="hemochromatosis.REF3">
              <mixed-citation publication-type="webpage">European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencedirect.com/science/article/pii/S0168827810001972">online</ext-link>. 2010. Accessed 9-14-15.</mixed-citation>
            </ref>
            <ref id="hemochromatosis.REF4">
              <mixed-citation publication-type="webpage">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">online</ext-link>. 2012. Accessed 9-14-15.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hemochromatosis.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hemochromatosis.Literature_Cited.reflist0">
            <ref id="hemochromatosis.REF.adams.2005.1769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reboussin</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eckfeldt</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dawkins</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acton</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leiendecker-Foster</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speechley</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snively</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holup</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sholinsky</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hemochromatosis and iron-overload screening in a racially diverse population.</article-title>
                <source>N Engl J Med</source>
                <volume>352</volume>
                <fpage>1769</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">15858186</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.albig.1998.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Albig</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drabent</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burmester</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bode</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doenecke</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>The haemochromatosis candidate gene HFE (HLA-H) of man and mouse is located in syntenic regions within the histone gene cluster.</article-title>
                <source>J Cell Biochem</source>
                <volume>69</volume>
                <fpage>117</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">9548560</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.allen.2010.925">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertalli</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osborne</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Constantine</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delatycki</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nisselle</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoll</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertig</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giles</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopper</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurrin</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <article-title>HealthIron Study Investigators. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis.</article-title>
                <source>Hepatology.</source>
                <year>2010</year>
                <volume>52</volume>
                <fpage>925</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">20583211</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.allen.2008.221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurrin</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Constantine</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osborne</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delatycki</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoll</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bahlo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nisselle</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vulpe</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Southey</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giles</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>English</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopper</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertig</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Iron-overload-related disease in HFE hereditary hemochromatosis.</article-title>
                <source>N Engl J Med.</source>
                <volume>358</volume>
                <fpage>221</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">18199861</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.andersen.2004.2914">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>RV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tybjaerg-Hansen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appleyard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birgens</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordestgaard</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hemochromatosis mutations in the general population: iron overload progression rate.</article-title>
                <source>Blood</source>
                <volume>103</volume>
                <fpage>2914</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15070663</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.bacon.2011.328">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tavill</surname>
                    <given-names>AS</given-names>
                  </name>
                  <collab>American Association for the Study of Liver Diseases</collab>
                </person-group>
                <article-title>Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.</article-title>
                <source>Hepatology.</source>
                <year>2011</year>
                <volume>54</volume>
                <fpage>328</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">21452290</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.bardoujacquet.2015a.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bardou-Jacquet</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lain&#x000e9;</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deugnier</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>Reply to: "Reduced mortality due to phlebotomy in moderately iron-loaded HFE Haemochromatosis? The need for clinical trials</article-title>
                <source>J Hepatol.</source>
                <year>2015a</year>
                <volume>63</volume>
                <fpage>283</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">25841362</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.bardoujacquet.2015b.682">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bardou-Jacquet</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morcet</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lain&#x000e9;</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouanolle</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guyader</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moirand</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viel</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deugnier</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis.</article-title>
                <source>J Hepatol.</source>
                <year>2015b</year>
                <volume>62</volume>
                <fpage>682</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">25450707</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.bardoujacquet.2015c">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bardou-Jacquet</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Tayrac</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mosser</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deugnier</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>GNPAT Variant associated with severe iron overload in HFE hemochromatosis.</article-title>
                <source>Hepatology.</source>
                <year>2015c</year>
                <month>Apr</month>
                <day>18</day>
                <comment>Epub ahead of print</comment>
                <pub-id pub-id-type="pmid">25891252</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.barton.1998.932">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonnell</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brissot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>CQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cook</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Management of hemochromatosis. Hemochromatosis Management Working Group.</article-title>
                <source>Ann Intern Med</source>
                <volume>129</volume>
                <fpage>932</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9867745</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.beutler.2002.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beutler</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Felitti</surname>
                    <given-names>VJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koziol</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gelbart</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Penetrance of 845G--&#x0003e; A (C282Y) HFE hereditary haemochromatosis mutation in the USA.</article-title>
                <source>Lancet</source>
                <volume>359</volume>
                <fpage>211</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11812557</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.brittenham.2003.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brittenham</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badman</surname>
                    <given-names>DG</given-names>
                  </name>
                  <collab>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop</collab>
                </person-group>
                <article-title>Noninvasive measurement of iron: report of an NIDDK workshop.</article-title>
                <source>Blood.</source>
                <year>2003</year>
                <volume>101</volume>
                <fpage>15</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12393526</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.bulaj.1996.1799">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bulaj</surname>
                    <given-names>ZJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffen</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jorde</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>CQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Clinical and biochemical abnormalities in people heterozygous for hemochromatosis.</article-title>
                <source>N Engl J Med</source>
                <volume>335</volume>
                <fpage>1799</fpage>
                <lpage>805</lpage>
                <pub-id pub-id-type="pmid">8943161</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.camaschella.2000.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garozzo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majorano</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.</article-title>
                <source>Nat Genet</source>
                <volume>25</volume>
                <fpage>14</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10802645</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.cheong.2005.448">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cheong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huber</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muthupillai</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flamm</surname>
                    <given-names>SD</given-names>
                  </name>
                </person-group>
                <article-title>Evaluation of myocardial ironoverload by T2* cardiovascular magnetic resonance imaging.</article-title>
                <source>Tex Heart Inst J.</source>
                <year>2005</year>
                <volume>32</volume>
                <fpage>448</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16392242</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.crawford.2004.1655">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hubscher</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuart</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gane</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angus</surname>
                    <given-names>PW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffrey</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCaughan</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerlin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elias</surname>
                    <given-names>EE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis.</article-title>
                <source>Hepatology</source>
                <volume>39</volume>
                <fpage>1655</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">15185307</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.de_gobbi.2002.973">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papanikolaou</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Politou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lockitch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girelli</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargion</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Natural history of juvenile haemochromatosis.</article-title>
                <source>Br J Haematol</source>
                <volume>117</volume>
                <fpage>973</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12060140</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.delatycki.2015.282">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Delatycki</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurrin</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ong</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramm</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoll</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                </person-group>
                <article-title>Reduced mortality due to phlebotomy in moderately iron-loaded HFE haemochromatosis? The need for clinical trials.</article-title>
                <source>J Hepatol.</source>
                <year>2015</year>
                <volume>63</volume>
                <fpage>282</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">25839407</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.dubois.2004.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>DuBois</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Review article: targeted screening for hereditary haemochromatosis in high-risk groups.</article-title>
                <source>Aliment Pharmacol Ther</source>
                <volume>20</volume>
                <fpage>1</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">15225165</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.eijkelkamp.2000.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eijkelkamp</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yapp</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>HFE-associated hereditary hemochromatosis.</article-title>
                <source>Can J Gastroenterol</source>
                <volume>14</volume>
                <fpage>121</fpage>
                <pub-id pub-id-type="pmid">10694284</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.elserag.2000.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>El-Serag</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inadomi</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis.</article-title>
                <source>Ann Intern Med</source>
                <volume>132</volume>
                <fpage>261</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10681280</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.european_association_for_the_study_of_the_liver.2010.3">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>European Association for the Study of the Liver</collab>
                </person-group>
                <article-title>EASL clinical practice guidelines for HFE hemochromatosis.</article-title>
                <source>J Hepatol.</source>
                <year>2010</year>
                <volume>53</volume>
                <fpage>3</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">20471131</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.feder.1996.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feder</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gnirke</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuchihashi</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruddy</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basava</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dormishian</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Domingo</surname>
                    <given-names>R</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Ellis</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fullan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hinton</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimmel</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kronmal</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loeb</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mapa</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClelland</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mintier</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moeller</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morikang</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prass</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quintana</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Starnes</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schatzman</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunke</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drayna</surname>
                    <given-names>DT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risch</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolff</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.</article-title>
                <source>Nat Genet</source>
                <volume>13</volume>
                <fpage>399</fpage>
                <lpage>408</lpage>
                <pub-id pub-id-type="pmid">8696333</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.fischer.2009.215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harmatz</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Non-invasive assessment of tissue iron overload.</article-title>
                <source>Hematology Am Soc Hematol Educ Program.</source>
                <fpage>215</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">20008201</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.fleming.2004.755">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Britton</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waheed</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sly</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Pathogenesis of hereditary hemochromatosis.</article-title>
                <source>Clin Liver Dis</source>
                <volume>8</volume>
                <fpage>755</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">15464654</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.fletcher.2002.281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purdie</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>DH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis.</article-title>
                <source>Gastroenterology</source>
                <volume>122</volume>
                <fpage>281</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11832443</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.friedrichrust.2008.960">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friedrich-Rust</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martens</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarrazin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bojunga</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeuzem</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrmann</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Performance of transient elastography for the staging of liver fibrosis: A meta-analysis.</article-title>
                <source>Gastroenterology</source>
                <volume>134</volume>
                <fpage>960</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">18395077</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.gan.2011.293">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gan</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                </person-group>
                <article-title>Natural history and management of HFE-hemochromatosis.</article-title>
                <source>Semin Liver Dis.</source>
                <year>2011</year>
                <volume>31</volume>
                <fpage>293</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">21901659</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.gochee.2002.646">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gochee</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cullen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du Sart</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.</article-title>
                <source>Gastroenterology</source>
                <volume>122</volume>
                <fpage>646</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">11874997</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.gurrin.2009.94">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gurrin</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertalli</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalton</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osborne</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Constantine</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>English</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertig</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delatycki</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoll</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Southey</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopper</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giles</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>KJ</given-names>
                  </name>
                </person-group>
                <article-title>HealthIron Study Investigators. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-relatedmorbidity.</article-title>
                <source>Hepatology.</source>
                <year>2009</year>
                <volume>50</volume>
                <fpage>94</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">19554541</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.gurrin.2008.1945">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gurrin</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osborne</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Constantine</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>English</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gertig</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delatycki</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Southey</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopper</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giles</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>KJ</given-names>
                  </name>
                </person-group>
                <article-title>HealthIron Study Investigators. The natural history of serum ironindices for HFE C282Y homozygosity associated with hereditary hemochromatosis.</article-title>
                <source>Gastroenterology.</source>
                <year>2008</year>
                <volume>135</volume>
                <fpage>1945</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">18848943</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.kowdley.2005.494">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandhagen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gish</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bass</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schilsky</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontana</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCashland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotler</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keeffe</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polissar</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry.</article-title>
                <source>Gastroenterology</source>
                <volume>129</volume>
                <fpage>494</fpage>
                <lpage>503</lpage>
                <pub-id pub-id-type="pmid">16083706</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.kowdley.2012.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeh</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuschwander-Tetri</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chalasani</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanyal</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>JE</given-names>
                  </name>
                  <collab>NASH Clinical Research Network</collab>
                </person-group>
                <article-title>Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.</article-title>
                <source>Hepatology.</source>
                <year>2012</year>
                <volume>55</volume>
                <fpage>77</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">21953442</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.le_gac.2010.685">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Le Gac</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Congiu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gourlaouen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000e9;rec</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melis</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Homozygous deletion of HFE is the common cause of hemochromatosis in Sardinia.</article-title>
                <source>Haematologica.</source>
                <year>2010</year>
                <volume>95</volume>
                <fpage>685</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20007136</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.lebr_n.1998.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lebr&#x000f3;n</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaughn</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chirino</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snow</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mintier</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feder</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bjorkman</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor.</article-title>
                <source>Cell</source>
                <volume>93</volume>
                <fpage>111</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">9546397</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.lee.2012.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaasterland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Mild iron overload in an African American man with SLC40A1 D270V.</article-title>
                <source>Acta Haematol</source>
                <volume>128</volume>
                <fpage>28</fpage>
                <pub-id pub-id-type="pmid">22584997</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.mart_nez.2011.325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mart&#x000ed;nez</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crespo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Navasa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forns</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Noninvasive assessment of liver fibrosis.</article-title>
                <source>Hepatology</source>
                <volume>53</volume>
                <fpage>325</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">21254180</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.mattman.2002.1075">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mattman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huntsman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lockitch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langlois</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buskard</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ralston</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butterfield</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodrigues</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porto</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marra</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Sousa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vatcher</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation.</article-title>
                <source>Blood</source>
                <volume>100</volume>
                <fpage>1075</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12130528</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.mclaren.2015.429">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emond</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramaniam</surname>
                    <given-names>VN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phatak</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <article-title>Goh JB3, McDonald CJ, Powell LW, Gurrin LC, Allen KJ, Nickerson DA, Louie T, Ramm GA, Anderson GJ, McLaren GD. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.</article-title>
                <source>Hepatology.</source>
                <year>2015</year>
                <volume>62</volume>
                <fpage>429</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">25605615</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.mclaren.1998.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLachlan</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halliday</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leggett</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jazwinska</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis.</article-title>
                <source>Gastroenterology</source>
                <volume>114</volume>
                <fpage>543</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9496946</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.mcnamara.2005.1855">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McNamara</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacPhail</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Ferroportin (Q248H) mutations in African families with dietary iron overload.</article-title>
                <source>J Gastroenterol Hepatol.</source>
                <volume>20</volume>
                <fpage>1855</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16336444</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.montosi.2001.619">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Montosi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donovan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garuti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignatti</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassanelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trenor</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andrews</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.</article-title>
                <source>J Clin Invest</source>
                <volume>108</volume>
                <fpage>619</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">11518736</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.morrison.2003.627">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morrison</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandhagen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phatak</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krawitt</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Serag</surname>
                    <given-names>HB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galan</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tung</surname>
                    <given-names>BY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ioannou</surname>
                    <given-names>GN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis.</article-title>
                <source>Ann Intern Med</source>
                <volume>138</volume>
                <fpage>627</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">12693884</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.nelson.2011.448">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunt</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeh</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleiner</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unalp-Arida</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                  <collab>Nonalcoholic Steatohepatitis Clinical Research Network</collab>
                </person-group>
                <year>2011</year>
                <article-title>Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease.</article-title>
                <source>Hepatology.</source>
                <volume>53</volume>
                <fpage>448</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">21274866</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.njajou.2001.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Njajou</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaessen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joosse</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berghuis</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Dongen</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breuning</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snijders</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutten</surname>
                    <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandkuijl</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oostra</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Duijn</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heutink</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.</article-title>
                <source>Nat Genet</source>
                <volume>28</volume>
                <fpage>213</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11431687</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.olynyk.2004.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagan</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cullen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beilby</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whittall</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study.</article-title>
                <source>Mayo Clin Proc</source>
                <volume>79</volume>
                <fpage>309</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">15008603</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.pedersen.2009.775">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pedersen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milman</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Genetic screening for HFE hemochromatosis in 6,020 Danish men: penetrance of C282Y, H63D, and S65C variants.</article-title>
                <source>Ann Hematol.</source>
                <volume>88</volume>
                <fpage>775</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">19159930</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.phatak.2008.270">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phatak</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonkovsky</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowdley</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Hereditary hemochromatosis: time for targeted screening.</article-title>
                <source>Ann Intern Med.</source>
                <volume>149</volume>
                <fpage>270</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">18711158</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.phatak.2010.1671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phatak</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brissot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wurster</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonkovsky</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malfertheiner</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niederau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoelzel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stremmel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.</article-title>
                <source>Hepatology.</source>
                <year>2010</year>
                <volume>52</volume>
                <fpage>1671</fpage>
                <lpage>779</lpage>
                <pub-id pub-id-type="pmid">20814896</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.pietrangelo.2004.131">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pietrangelo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The ferroportin disease.</article-title>
                <source>Blood Cells Mol Dis</source>
                <volume>32</volume>
                <fpage>131</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14757427</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.piperno.2000.441">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arosio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fossati</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vigan&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trombini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vergani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancia</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis.</article-title>
                <source>Gastroenterology</source>
                <volume>119</volume>
                <fpage>441</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10930379</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.powell.2006.294">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>LW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dixon</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramm</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purdie</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Screening for hemochromatosis in asymptomatic subjects with or without a family history.</article-title>
                <source>Arch Intern Med</source>
                <volume>166</volume>
                <fpage>294</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">16476869</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.pronicka.2011.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pronicka</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x00119;glewska-Jurkiewicz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taybert</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pronicki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szyma&#x00144;ska-D&#x00119;bi&#x00144;ska</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karkuci&#x00144;ska-Wi&#x00119;ckowska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jak&#x000f3;bkiewicz-Banecka</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowalski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piekutowska-Abramczuk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pajdowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Socha</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sykut-Cegielska</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x00119;grzyn</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Post mortem identification of deoxyguanosine kinase (DGUOK) gene mutations combined with impaired glucose homeostasis and iron overload features in four infants with severe progressive liver failure.</article-title>
                <source>J Appl Genet.</source>
                <volume>52</volume>
                <fpage>61</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21107780</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.ptaszek.2005.689">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ptaszek</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Price</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <article-title>Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging.</article-title>
                <source>J Cardiovasc Magn Reson.</source>
                <year>2005</year>
                <volume>7</volume>
                <fpage>689</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16136860</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.ramazzotti.2009.62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ramazzotti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Positano</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Marchi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brizi</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luciani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Midiri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sallustio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valeri</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Centra</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cianciulli</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Sanctis</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maggio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lombardi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron.</article-title>
                <source>J Magn Reson Imaging.</source>
                <volume>30</volume>
                <fpage>62</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19557847</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.ramrakhiani.1998.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ramrakhiani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacon</surname>
                    <given-names>BR</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Hemochromatosis: advances in molecular genetics and clinical diagnosis.</article-title>
                <source>J Clin Gastroenterol</source>
                <volume>27</volume>
                <fpage>41</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">9706768</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.rivers.2007.247">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rivers</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barton</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordeuk</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acton</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speechley</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snively</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leiendecker-Foster</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Press</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dawkins</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLaren</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reboussin</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <year>2007</year>
                <volume>38</volume>
                <fpage>247</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">17276706</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.roetto.1999.1388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Totaro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazzola</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cicilano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Ascola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carella</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zelante</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Juvenile hemochromatosis locus maps to chromosome 1q.</article-title>
                <source>Am J Hum Genet</source>
                <volume>64</volume>
                <fpage>1388</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">10205270</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.scotet.2003.129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scotet</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merour</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercier</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chanu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Faou</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raguenes</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Gac</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mura</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nousbaum</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferec</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation.</article-title>
                <source>Am J Epidemiol</source>
                <volume>158</volume>
                <fpage>129</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">12851225</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.sherman.2010.610">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sherman</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>The radiological diagnosis of hepatocellular carcinoma.</article-title>
                <source>Am J Gastroenterol.</source>
                <year>2010</year>
                <volume>105</volume>
                <fpage>610</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">20203642</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.st_pierre.2005.855">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>St Pierre</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chua-anusorn</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleming</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeffrey</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olynyk</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pootrakul</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robins</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindeman</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>855</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15256427</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.tavill.2001.1321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tavill</surname>
                    <given-names>AS</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Diagnosis and management of hemochromatosis.</article-title>
                <source>Hepatology</source>
                <volume>33</volume>
                <fpage>1321</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11343262</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.tsochatzis.2011.650">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsochatzis</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurusamy</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ntaoula</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cholongitas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burroughts</surname>
                    <given-names>AK</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy.</article-title>
                <source>J Hepatol</source>
                <volume>54</volume>
                <fpage>650</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21146892</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.whitlock.2006.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Whitlock</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garlitz</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beil</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>PR</given-names>
                  </name>
                </person-group>
                <article-title>Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.</article-title>
                <source>Ann Intern Med.</source>
                <year>2006</year>
                <volume>145</volume>
                <fpage>209</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">16880463</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.yamashita.2003.388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>PC</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level.</article-title>
                <source>Clin Gastroenterol Hepatol</source>
                <volume>1</volume>
                <fpage>388</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15017658</pub-id>
              </element-citation>
            </ref>
            <ref id="hemochromatosis.REF.yu.2007.489">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ioannou</surname>
                    <given-names>GN</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Survival of liver transplant recipients with hemochromatosis in the United States.</article-title>
                <source>Gastroenterology.</source>
                <volume>133</volume>
                <fpage>489</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">17681170</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hemochromatosis.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hemochromatosis.Author_History">
          <title>Author History</title>
          <p>Robin L Bennett, MS; University of Washington (2000-2015)Kris V Kowdley, MD; Virginia Mason Medical Center (2000-2015)Arno G Motulsky, MD; University of Washington (2000-2015)Lawrie Powell, AC, MD, PhD (2015-present)Rebecca Seckington (2015-present)Jonathan F Tait, MD, PhD; University of Washington School of Medicine (2000-2011)</p>
        </sec>
        <sec id="hemochromatosis.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 September 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 April 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>4 December 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>13 July 2005 (kk) Revision: sequence analysis of entire coding region clinically available</p>
            </list-item>
            <list-item>
              <p>13 September 2004 (kk) Author revisions</p>
            </list-item>
            <list-item>
              <p>7 October 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>3 April 2000 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>October 1998 (kk) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="hemochromatosis.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Algorithm for screening for <italic toggle="yes">HFE</italic>-associated hemochromatosis using LFT (liver function test) and TS (transferrin saturation) <italic toggle="yes">O</italic>riginally published in <xref ref-type="bibr" rid="hemochromatosis.REF.eijkelkamp.2000.121">Eijkelkamp et al [2000]</xref>; reused with permission</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hemochromatosis-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="hemochromatosis.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Use of serum ferritin concentration to help direct management</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hemochromatosis-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
